AMEX: AEON

AEON Biopharma, Inc.

Healthcare | Biotechnology

$0.21 as of 2026-09-05 19:05 UTC

Market Cap$10M

Volume39.82M

AEON Biopharma, Inc. (AMEX: AEON) is a $10M biotechnology company trading at $0.21. Figures from SEC EDGAR and market feeds; updated 2026-09-05 19:05 UTC.

What AEON Biopharma, Inc. does

AEON Biopharma is a biopharmaceutical company developing ABP-450, a botulinum toxin complex designed as a biosimilar to the branded drug Botox for therapeutic medical indications. The company holds exclusive development and commercialization rights for ABP-450 in the United States, Canada, the European Union, the United Kingdom, and certain other international territories, and is pursuing approval through the FDA's biosimilar pathway. ABP-450 is already approved for aesthetic use in the United States under the brand name Jeuveau and is marketed in multiple international markets.

Summarized from AEON Biopharma, Inc.’s SEC filings · Read the filing ↗

Key facts

Quote	19:05 UTC
Price	$0.21
Market cap	$10M
Volume	39.82M shares

Price Chart

Interactive chart available in terminalLive price charts with full OHLCV data, volume overlay, and technical indicators.
Open AEON in Platform →

SEC Filings

SEC EDGAR ↗

Recent Insider Activity (last 90 days)

Source: SEC EDGAR · Filed 2026-08-21

2026-08-21LYNCH TIMOTHY PBUY1,150,000$243.5K
2026-06-22Thunen Shelley BA222,684—
2026-06-22PALMISANO ROBERT JA222,684—

Top Institutional Holders (latest 13F)

Source: SEC EDGAR · As of 2026-Q1

Dauntless Investment Group, LLC2,527,775$2.49M+18.6%
SABBY MANAGEMENT, LLC449,687$260.6KNEW
VANGUARD GROUP INC100,333$110.4K+1.8%

View QoQ ownership changes →Full institutional ownership →

Recent 8-K Events (parsed from SEC filings)All events →

Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

2026-03-09Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →

Company news

View all →

AEON Biopharma Designates Paul Lee As Chief Regulatory Office
Benzinga2026-08-24
AEON Biopharma Announces Final, Expanded Primary Structure Results And Preliminary Disulfide Bond Characterization Data Providing Complementary Evidence Supporting Molecular Similarity Of ABP-450 To BOTOX
Benzinga2026-08-19POS
HC Wainwright & Co. Maintains Buy on AEON Biopharma, Lowers Price Target to $1.2
Benzinga2026-08-14
AEON Biopharma Q2 EPS $(0.02) Beats $(0.12) Estimate
Benzinga2026-08-12POS
AEON Biopharma Regains NYSE American Compliance
Benzinga2026-08-03POS

Questions this page answers

What does AEON Biopharma, Inc. do?

AEON Biopharma is a biopharmaceutical company developing ABP-450, a botulinum toxin complex designed as a biosimilar to the branded drug Botox for therapeutic medical indications.

What is AEON's valuation?

AEON trades at $0.21, as of 2026-09-05.

When did AEON last file with the SEC?

AEON Biopharma, Inc.'s most recent SEC filing on record is a 10-Q filed 2026-08-12. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings and public market data feeds, fetched 2026-09-05 19:05 UTC. This page is also available as JSON at /api/data?ticker=AEON and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for AEON and 5,000+ tickers.

Create a free account — keep AEON

For your agent

GET /api/data?ticker=AEON

This page as JSON via rel="alternate" · REST API docs · MCP server (59 tools) · llms.txt